Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-02-17
2009-10-06
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07598287
ABSTRACT:
The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent.
REFERENCES:
patent: 4244946 (1981-01-01), Rivier et al.
patent: 4305872 (1981-12-01), Johnston et al.
patent: 4316891 (1982-02-01), Guillemin et al.
patent: 4629784 (1986-12-01), Stammer
patent: 4792525 (1988-12-01), Ruoslahti et al.
patent: 4868116 (1989-09-01), Morgan et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5244807 (1993-09-01), Murtfeldt et al.
patent: 5478556 (1995-12-01), Elliott et al.
patent: 5723325 (1998-03-01), Murtfeldt et al.
patent: 5837231 (1998-11-01), Low et al.
patent: 5861159 (1999-01-01), Pardoll et al.
patent: 5874560 (1999-02-01), Kawakami et al.
patent: 6251399 (2001-06-01), Diamond et al.
patent: 6395876 (2002-05-01), Munn et al.
patent: 6451840 (2002-09-01), Munn et al.
patent: 6482416 (2002-11-01), Munn et al.
patent: 7098209 (2006-08-01), Orme et al.
patent: 7160539 (2007-01-01), Munn et al.
patent: 2002/0114784 (2002-08-01), Li et al.
patent: 2002/0155104 (2002-10-01), Munn et al.
patent: 2003/0194803 (2003-10-01), Mellor et al.
patent: 2004/0152705 (2004-08-01), Orme et al.
patent: 2004/0161425 (2004-08-01), Munn et al.
patent: 2004/0234623 (2004-11-01), Munn et al.
patent: 2005/0142078 (2005-06-01), Dorr et al.
patent: 2005/0186289 (2005-08-01), Munn et al.
patent: 2006/0292618 (2006-12-01), Mellor et al.
patent: 2007/0048769 (2007-03-01), Mellor et al.
patent: 2007/0077234 (2007-04-01), Munn et al.
patent: 2007/0099844 (2007-05-01), Prendergast et al.
patent: 2007/0105907 (2007-05-01), Prendergast et al.
patent: 2007/0173524 (2007-07-01), Prendergast et al.
patent: 2003206496 (2003-09-01), None
patent: 2002307243 (2003-10-01), None
patent: 2003267088 (2004-04-01), None
patent: 2003206496 (2007-08-01), None
patent: 2002307243 (2008-01-01), None
patent: 2445625 (2002-12-01), None
patent: 2475985 (2003-09-01), None
patent: 2483451 (2003-10-01), None
patent: 0 385 385 (1990-09-01), None
patent: 1 392 688 (2008-06-01), None
patent: 2004532889 (2004-10-01), None
patent: 2005524652 (2005-08-01), None
patent: 3011082 (2004-06-01), None
patent: WO 93/01286 (1993-01-01), None
patent: 99/29310 (1999-06-01), None
patent: 99/29852 (1999-06-01), None
patent: 00/66764 (2000-11-01), None
patent: WO 02/98877 (2002-12-01), None
patent: WO 03/072072 (2003-09-01), None
patent: WO 03/087347 (2003-10-01), None
patent: WO 2004/024075 (2004-03-01), None
patent: WO 2004/024075 (2004-10-01), None
patent: WO 2004/093871 (2004-11-01), None
patent: WO 2004/094409 (2004-11-01), None
patent: WO 2007/050405 (2007-05-01), None
patent: WO 2007/081878 (2007-07-01), None
Gura et al;. System for identifying new drugs are often faulty. Science, 1997, 278:1041-1042.
Johnson et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. British J. of Cancer, 2001, 84(10):1424-1431.
Muller et al. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin. Ther. Targets, 2005, vol. 9, No. 4, pp. 831-849.
Tsung et al. The Journal of Immunology, 1998, vol. 160, pp. 1369-1377.
Pinedo et al. The Oncologist, 2000, vol. 5, pp. 497-500.
Alberti-Giani, “Regulation of the Kynurenine Metabolic Pathway by Interferon-γ in Murine Cloned Macrophages and Microglial Cells,”J. Neurochem, 1996;66:996-1004.
Alexander et al., “Indoleamine 2,3-Dioxygenase Expression in Transplanted NOD Islets Prolongs Graft Survival After Adoptive Transfer of Diabetogenic Splenocytes,”Diabetes, 2002;51:356-365.
Almand et al., “Clinical Significance of Defective Dendritic Cell Differentiation in Cancer,”Clin. Cancer Res., 2000;6:1755-1766.
Asselin-Paturel et al., “Mouse type IIFN-producing cells are immature APCs with plasmacytoid morphology,”Nat. Immunol., 2001;2:1144-1150.
Aune et al., “Inhibition of Tumor Cell Growth by Interferon-γ Is Mediated by Two Distinct Mechanisms Dependent upon Oxygen Tension: Induction of Tryptophan Degradation and Depletion of Intracellular Nicotinamide Adenine Dinucleotide,”J Clin Invest, 1989;84:863-875.
Azuma, et al., “B70 antigen is a second ligand for CTLA-4 and CD28,”Nature1993;366:76-79.
Ben-Efraim, “Immunomodulating Anticancer Alkylating Drugs: Targets and Mechanisms of Activity,”Current Drug Targets, 2001;2:197-212.
Benson et al., “T-cell activation and receptor downmodulation precede deletion induced by mucosally administered antigen,”J. Clin. Invest., 2000;106:1031-1038.
Bjorck et al., “Cutting Edge: CD19+ Pro-B Cells Can Give Rise to Dendritic Cells In Vitro, ”J. Immunol., 1998;161:5795-5799.
Borrello et al., “A Universal Granulocyte-Macrophage Colony-Stimulating Factor-Producing Bystander Cell Line for Use in the Formulation of Autologous Tumor Cell-Based Vaccine,”Hum. Gene. Ther., 1990;10:1983-1991.
Bronte et al., “Unopposed Production of Granulocyte-Macrophage Colony-Stimulating Factor by Tumors Inhibits CD8+ T Cell Responses by Dysregulating Antigen-Presenting Cell Maturation,”J. Immunol., 1999;162:5728-5737.
Carlin et al., “Intrferon-Induced Indoleamine 2,3-Dioxygenase Activity in Human Mononuclear Phagocytes,”J. Leuk. Biol. 1989;45:29-34.
Cella et al., “Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon,”Nat. Med., 1999;5:919-923.
Chambers, “The expanding world of co-stimulation: the two-signal model revisited,”Trend Immunol. 2001;22:217-223.
Chen et al., “The Role of Tumor Necrosis Factor α in Modulating the Quantity of Peripheral Blood-Derived, Cytokine-Driven Human Dendritic Cells and Its Role in Enhancing the Quality of Dendritic Cell Function in Presenting Soluble Antigens to CD4+ T Cells in Vitro,”Blood, 1998;91:4652-4661.
Chon, “Cooperative Role of Interferon Regulatory Factor 1 and p91 (STAT1) Response Elements in Interferon-γ-inducible Expression of Human Indoleamine 2,3-Dioxygenase Gene,”J Biol Chem, 1996;271:17247-17252.
Cochran et al., “Sentinel Lymph Nodes Show Profound Downregulation of Antigen-Presenting Cells of the Pracortex: Implications for Tumor Biology and Treatment,”Mod. Pathol., 2001;14:604-608.
Colasante et al., “Role of Cytokines in Distribution and Differentiation of Dendritic Cell/Langerhans' Cell Lineage in Human Primary Carcinomas of the Lung,”Hum. Pathol., 1995;26:866-872.
Corbett et al., “Response of Transplantable Tumors of Mice to Anthracenedione Derivatives Alone and in Combination with Clinically Useful Agents,”Cancer Treatment Reports, 1982;66:1187-1200.
Corcoran et al., “The lumphoid Past of Mouse Plasmacytoid Cells and Thymic Dendritic Cells,”J. of Immunology, 2003;170:4926-4932.
Cuenca et al., “Extra-Lymphatic Solid Tumor Growth Is Not Immunologically Ignorned and Results in Early Induction of Antigen-Specific T-Cell Anergy: Dominant Role of Cross-Tolerance to Tumor Antigens,”Cancer Res., 2003;63:9007-9015.
Curreli et al., “Human Primary CD+ T Cells Activated in the Presence of IFN-α2b Express Functional Indoleamine 2,3-Dioxygenase,”J. Interferon Cytokine Res., 2001;21:431-437.
Dai et al., “Molecular Clong, sequencing and expression of human interferon-gamma-inducible indoleamine 2,3-dioxygenase cDNA,”Biochem. Biophys. Res. Commun., 1990;168:1-8 GenBank Accession No. M34455.
Daubener, “Establishment of T-helper type 1- and T-helper type 2-like humanToxoplasmaantigen-specific T-cell clones,”Immunol. 1995;86:79-84.
Daubener, et al., “Anti-parasitic effector mechanisms in human brain tumor cells: role of interferon-γ and tumor necrosis factor-α,”Eur. J. Immunol. 1996;26:487-492.
Dranoff, “GM-CSF-based cancer vaccines,”Immunol. Rev. 2002;188:147-154.
Dranoff et al
Mellor Andrew
Munn David
Anderson James D
Cooley Godward Kronish LLP
Marschel Ardin
Medical College of Georgia Research Institute Inc.
LandOfFree
Use of inhibitors of indoleamine-2,3-dioxygenase in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of inhibitors of indoleamine-2,3-dioxygenase in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of inhibitors of indoleamine-2,3-dioxygenase in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4070033